Polycystic ovary syndrome: Do endocrine-disrupting chemicals play a role?

Seminars in Reproductive Medicine

Volumn 32, Issue 3, 2014, Pages 166-176

  Barrett, Emily S ^a   Sobolewski, Marissa ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Bisphenol A; BPA; EDCs; Endocrine disrupting chemicals; PCOS

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BENZHYDRYL DERIVATIVE; ENDOCRINE DISRUPTOR; PHENOL DERIVATIVE;

ARTICLE; ENDOCRINE DISEASE; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; METABOLIC DISORDER; NONHUMAN; OVARY DEVELOPMENT; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PERINATAL DRUG EXPOSURE; ADULT; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; PREGNANCY;

ADULT; ANIMALS; BENZHYDRYL COMPOUNDS; DISEASE MODELS, ANIMAL; ENDOCRINE DISRUPTORS; FEMALE; HUMANS; PHENOLS; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 84898429825     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0034-1371088     Document Type: Article

References (108)

1. Dasgupta S., Sirisha P. V., Neelaveni K., et al. Androgen receptor CAG repeat polymorphism and epigenetic influence among the south Indian women with Polycystic Ovary Syndrome. PLoS ONE: 2010; 5 8 e12401
2. Hickey T. E., Legro R. S., Norman R. J. Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. J Clin Endocrinol Metab: 2006; 91 7 2789 2791 (Pubitemid 44024652)
3. Li Z., Huang H. Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome. Med Hypotheses: 2008; 70 3 638 642 (Pubitemid 351193031)
4. Menke M. N., Strauss J. F. III. Genetic approaches to polycystic ovarian syndrome. Curr Opin Obstet Gynecol: 2007; 19 4 355 359 (Pubitemid 47067099)
5. Diamanti-Kandarakis E., Kandarakis H., Legro R. S. The role of genes and environment in the etiology of PCOS. Endocrine: 2006; 30 1 19 26 (Pubitemid 46020326)
6. Lim S. S., Norman R. J., Davies M. J., Moran L. J. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev: 2013; 14 2 95 109
7. Panidis D., Tziomalos K., Papadakis E., Vosnakis C., Chatzis P., Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine: 2013; 44 3 583 590
8. Moran L. J., Pasquali R., Teede H. J., Hoeger K. M., Norman R. J. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril: 2009; 92 6 1966 1982
9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod: 2004; 19 1 41 47
10. Azziz R., Carmina E., Dewailly D., et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril: 2009; 91 2 456 488
11. Guerrero-Bosagna C. M., Skinner M. K. Environmental epigenetics and phytoestrogen/phytochemical exposures. J Steroid Biochem Mol Biol: 2014; 139 270 276
12. Colborn T. Neurodevelopment and endocrine disruption. Environ Health Perspect: 2004; 112 9 944 949 (Pubitemid 38931101)
13. Woodruff T. J. Bridging epidemiology and model organisms to increase understanding of endocrine disrupting chemicals and human health effects. J Steroid Biochem Mol Biol: 2011; 127 1-2 108 117
14. Anonymous. State of the Science of Endocrine Disrupting Chemicals-2012. In: Bergman A., Heindel J. J., Jobling S., et al. eds. Geneva, Switzerland World Health Organization: 2012
15. Welshons W. V., Nagel S. C., vom Saal F. S. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology: 2006; 147 (6, Suppl): S56 S69 (Pubitemid 43778691)
16. Matsushima A., Kakuta Y., Teramoto T., et al. Structural evidence for endocrine disruptor bisphenol A binding to human nuclear receptor ERR gamma. J Biochem: 2007; 142 4 517 524 (Pubitemid 351197677)
17. Koch H. M., Calafat A. M. Human body burdens of chemicals used in plastic manufacture. Philos Trans R Soc Lond B Biol Sci: 2009; 364 1526 2063 2078
18. Woodruff T. J., Zota A. R., Schwartz J. M. Environmental chemicals in pregnant women in the United States: NHANES 2003-2004. Environ Health Perspect: 2011; 119 6 878 885
19. Vandenberg L. N., Colborn T., Hayes T. B., et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev: 2012; 33 3 378 455
20. Kortenkamp A. Low dose mixture effects of endocrine disrupters: implications for risk assessment and epidemiology. Int J Androl: 2008; 31 2 233 240
21. Farquhar C. Introduction and history of polycystic ovary syndrome. In: Kovacs G. T., Norman R., eds. Polycystic Ovary Syndrome. 2nd ed. Cambridge, UK Cambridge University Press: 2007
22. Fernández M., Bourguignon N., Lux-Lantos V., Libertun C. Neonatal exposure to bisphenol A and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ Health Perspect: 2010; 118 9 1217 1222
23. Vandenberg L. N., Hauser R., Marcus M., Olea N., Welshons W. V. Human exposure to bisphenol A (BPA). Reprod Toxicol: 2007; 24 2 139 177 (Pubitemid 47385100)
24. Carwile J. L., Ye X., Zhou X., Calafat A. M., Michels K. B. Canned soup consumption and urinary bisphenol A: a randomized crossover trial. JAMA: 2011; 306 20 2218 2220
25. Kang J. H., Kondo F., Katayama Y. Human exposure to bisphenol A. Toxicology: 2006; 226 2-3 79 89 (Pubitemid 44287164)
26. Rudel R. A., Gray J. M., Engel C. L., et al. Food packaging and bisphenol A and bis(2-ethyhexyl) phthalate exposure: findings from a dietary intervention. Environ Health Perspect: 2011; 119 7 914 920
27. Wetherill Y. B., Akingbemi B. T., Kanno J., et al. In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol: 2007; 24 2 178 198 (Pubitemid 47385095)
28. Kundakovic M., Champagne F. A. Epigenetic perspective on the developmental effects of bisphenol A. Brain Behav Immun: 2011; 25 6 1084 1093
29. Ikezuki Y., Tsutsumi O., Takai Y., Kamei Y., Taketani Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod: 2002; 17 11 2839 2841 (Pubitemid 35350898)
30. Zhou W., Liu J., Liao L., Han S., Liu J. Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Mol Cell Endocrinol: 2008; 283 1-2 12 18
31. Rosenfield R. L., Barnes R. B., Cara J. F., Lucky A. W. Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril: 1990; 53 5 785 791 (Pubitemid 20180464)
32. Diamanti-Kandarakis E., Christakou C., Marinakis E. Phenotypes and environmental factors: their influence in PCOS. Curr Pharm Des: 2012; 18 3 270 282
33. Masuno H., Iwanami J., Kidani T., Sakayama K., Honda K. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci: 2005; 84 2 319 327 (Pubitemid 40542291)
34. Hugo E. R., Brandebourg T. D., Woo J. G., Loftus J., Alexander J. W., Ben-Jonathan N. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ Health Perspect: 2008; 116 12 1642 1647
35. Phrakonkham P., Viengchareun S., Belloir C., Lombès M., Artur Y., Canivenc-Lavier M. C. Dietary xenoestrogens differentially impair 3T3-L1 preadipocyte differentiation and persistently affect leptin synthesis. J Steroid Biochem Mol Biol: 2008; 110 1-2 95 103
36. Wang J., Sun B., Hou M., Pan X., Li X. The environmental obesogen bisphenol A promotes adipogenesis by increasing the amount of 11β-hydroxysteroid dehydrogenase type 1 in the adipose tissue of children. Int J Obes (Lond): 2013; 37 7 999 1005
37. Nadal A., Alonso-Magdalena P., Soriano S., Quesada I., Ropero A. B. The pancreatic β-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetes. Mol Cell Endocrinol: 2009; 304 1-2 63 68
38. Alonso-Magdalena P., Ropero A. B., Carrera M. P., et al. Pancreatic insulin content regulation by the estrogen receptor ER α PLoS ONE: 2008; 3 4 e2069
39. Bastos Sales L., Kamstra J. H., Cenijn P. H., van Rijt L. S., Hamers T., Legler J. Effects of endocrine disrupting chemicals on in vitro global DNA methylation and adipocyte differentiation. Toxicol In Vitro: 2013; 27 6 1634 1643
40. Anway M. D., Skinner M. K. Epigenetic transgenerational actions of endocrine disruptors. Endocrinology: 2006; 147 (6, Suppl): S43 S49 (Pubitemid 43764589)
41. Shi D., Vine D. F. Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertil Steril: 2012; 98 1 185 193
42. Padmanabhan V., Veiga-Lopez A. Sheep models of polycystic ovary syndrome phenotype. Mol Cell Endocrinol: 2013; 373 1-2 8 20
43. Abbott D. H., Barnett D. K., Bruns C. M., Dumesic D. A. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update: 2005; 11 4 357 374 (Pubitemid 40895465)
44. de Zegher F., Lopez-Bermejo A., Ibáñez L. Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol Metab: 2009; 20 9 418 423
45. Virtue S., Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol: 2008; 6 9 e237
46. Newbold R. R., Bullock B. C., McLachlan J. A. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res: 1990; 50 23 7677 7681
47. Newbold R. R., Banks E. P., Bullock B., Jefferson W. N. Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer Res: 2001; 61 11 4325 4328 (Pubitemid 32685752)
48. Newbold R. R., Jefferson W. N., Padilla-Banks E. Long-term adverse effects of neonatal exposure to bisphenol A on the murine female reproductive tract. Reprod Toxicol: 2007; 24 2 253 258 (Pubitemid 47393609)
49. Newbold R. R., Jefferson W. N., Padilla-Banks E. Prenatal exposure to bisphenol A at environmentally relevant doses adversely affects the murine female reproductive tract later in life. Environ Health Perspect: 2009; 117 6 879 885
50. Honma S., Suzuki A., Buchanan D. L., Katsu Y., Watanabe H., Iguchi T. Low dose effect of in utero exposure to bisphenol A and diethylstilbestrol on female mouse reproduction. Reprod Toxicol: 2002; 16 2 117 122 (Pubitemid 34457183)
51. Howdeshell K. L., Hotchkiss A. K., Thayer K. A., Vandenbergh J. G., vom Saal F. S. Exposure to bisphenol A advances puberty. Nature: 1999; 401 (6755): 763 764 (Pubitemid 129515829)
52. Markey C. M., Luque E. H., Munoz De Toro M., Sonnenschein C., Soto A. M. In utero exposure to bisphenol A alters the development and tissue organization of the mouse mammary gland. Biol Reprod: 2001; 65 4 1215 1223 (Pubitemid 32927590)
53. Rubin B. S., Murray M. K., Damassa D. A., King J. C., Soto A. M. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. Environ Health Perspect: 2001; 109 7 675 680 (Pubitemid 32785423)
54. Schönfelder G., Flick B., Mayr E., Talsness C., Paul M., Chahoud I. In utero exposure to low doses of bisphenol A lead to long-term deleterious effects in the vagina. Neoplasia: 2002; 4 2 98 102 (Pubitemid 34218677)
55. Schönfelder G., Friedrich K., Paul M., Chahoud I. Developmental effects of prenatal exposure to bisphenol A on the uterus of rat offspring. Neoplasia: 2004; 6 5 584 594 (Pubitemid 39411096)
56. Vandenberg L. N., Maffini M. V., Wadia P. R., Sonnenschein C., Rubin B. S., Soto A. M. Exposure to environmentally relevant doses of the xenoestrogen bisphenol-A alters development of the fetal mouse mammary gland. Endocrinology: 2007; 148 1 116 127 (Pubitemid 46021444)
57. Calafat A. M., Ye X., Wong L. Y., Reidy J. A., Needham L. L. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect: 2008; 116 1 39 44
58. Program N. T. Low Dose Endocrine Disruptors Peer Review. Research Triangle Park, NC National Institute of Environmental Health Sciences: 2001
59. Adewale H. B., Jefferson W. N., Newbold R. R., Patisaul H. B. Neonatal bisphenol-a exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin-releasing hormone neurons. Biol Reprod: 2009; 81 4 690 699
60. Kato H., Ota T., Furuhashi T., Ohta Y., Iguchi T. Changes in reproductive organs of female rats treated with bisphenol A during the neonatal period. Reprod Toxicol: 2003; 17 3 283 288 (Pubitemid 36626949)
61. Markey C. M., Coombs M. A., Sonnenschein C., Soto A. M. Mammalian development in a changing environment: exposure to endocrine disruptors reveals the developmental plasticity of steroid-hormone target organs. Evol Dev: 2003; 5 1 67 75 (Pubitemid 36174980)
62. Fernández M., Bianchi M., Lux-Lantos V., Libertun C. Neonatal exposure to bisphenol A alters reproductive parameters and gonadotropin releasing hormone signaling in female rats. Environ Health Perspect: 2009; 117 5 757 762
63. Nguyen R. H., Umbach D. M., Parad R. B., Stroehla B., Rogan W. J., Estroff J. A. US assessment of estrogen-responsive organ growth among healthy term infants: piloting methods for assessing estrogenic activity. Pediatr Radiol: 2011; 41 5 633 642
64. Kandaraki E., Chatzigeorgiou A., Livadas S., et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab: 2011; 96 3 E480 E484
65. Takeuchi T., Tsutsumi O., Ikezuki Y., Takai Y., Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J: 2004; 51 2 165 169 (Pubitemid 38657551)
66. Tarantino G., Valentino R., Di Somma C., et al. Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol (Oxf): 2013; 78 3 447 453
67. Déchaud H., Ravard C., Claustrat F., de la Perrière A. B., Pugeat M. Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids: 1999; 64 5 328 334 (Pubitemid 29284333)
68. Hanioka N., Jinno H., Nishimura T., Ando M. Suppression of male-specific cytochrome P450 isoforms by bisphenol A in rat liver. Arch Toxicol: 1998; 72 7 387 394 (Pubitemid 28313907)
69. Yokota H., Iwano H., Endo M., et al. Glucuronidation of the environmental oestrogen bisphenol A by an isoform of UDP-glucuronosyltransferase, UGT2B1, in the rat liver. Biochem J: 1999; 340 Pt 2 405 409 (Pubitemid 29286559)
70. Takeuchi T., Tsutsumi O., Ikezuki Y., et al. Elevated serum bisphenol A levels under hyperandrogenic conditions may be caused by decreased UDP-glucuronosyltransferase activity. Endocr J: 2006; 53 4 485 491 (Pubitemid 44351499)
71. Guillemette C., Lévesque E., Beaulieu M., Turgeon D., Hum D. W., Bélanger A. Differential regulation of two uridine diphospho- glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology: 1997; 138 7 2998 3005
72. Takeuchi T., Tsutsumi O. Serum bisphenol A concentrations showed gender differences, possibly linked to androgen levels. Biochem Biophys Res Commun: 2002; 291 1 76 78 (Pubitemid 34681140)
73. Takeuchi T., Tsutsumi O., Nakamura N., et al. Gender difference in serum bisphenol A levels may be caused by liver UDP-glucuronosyltransferase activity in rats. Biochem Biophys Res Commun: 2004; 325 2 549 554 (Pubitemid 39458029)
74. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev: 2012; 33 6 981 1030
75. Willis D., Mason H., Gilling-Smith C., Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab: 1996; 81 1 302 309 (Pubitemid 26035038)
76. Zawadzki J., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J., Haseltine F., et al. eds. Polycystic Ovary Syndrome. Boston, MA Blackwell Scientific Publications: 1990; 377 384
77. Moran L., Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update: 2009; 15 4 477 488
78. Diamanti-Kandarakis E., Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf): 2007; 67 5 735 742 (Pubitemid 47620439)
79. Rizzo M., Berneis K., Hersberger M., et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod: 2009; 24 9 2286 2292
80. Pasquali R., Gambineri A., Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG: 2006; 113 10 1148 1159 (Pubitemid 44401208)
81. Vigil P., Contreras P., Alvarado J. L., Godoy A., Salgado A. M., Cortés M. E. Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome. Hum Reprod: 2007; 22 11 2974 2980 (Pubitemid 351696829)
82. Janesick A., Blumberg B. Endocrine disrupting chemicals and the developmental programming of adipogenesis and obesity. Birth Defects Res C Embryo Today: 2011; 93 1 34 50
83. Vom Saal F. S., Nagel S. C., Coe B. L., Angle B. M., Taylor J. A. The estrogenic endocrine disrupting chemical bisphenol A (BPA) and obesity. Mol Cell Endocrinol: 2012; 354 1-2 74 84
84. Harley K. G., Aguilar Schall R., Chevrier J., et al. Prenatal and postnatal bisphenol A exposure and body mass index in childhood in the CHAMACOS cohort. Environ Health Perspect: 2013; 121 4 514 520, e1-e6
85. Li D. K., Miao M., Zhou Z., et al. Urine bisphenol-A level in relation to obesity and overweight in school-age children. PLoS ONE: 2013; 8 6 e65399
86. Wang H. X., Zhou Y., Tang C. X., Wu J. G., Chen Y., Jiang Q. W. Association between bisphenol A exposure and body mass index in Chinese school children: a cross-sectional study. Environ Health: 2012; 11 79
87. Trasande L., Attina T. M., Blustein J. Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents. JAMA: 2012; 308 11 1113 1121
88. Carwile J. L., Michels K. B. Urinary bisphenol A and obesity: NHANES 2003-2006. Environ Res: 2011; 111 6 825 830
89. Melzer D., Rice N. E., Lewis C., Henley W. E., Galloway T. S. Association of urinary bisphenol A concentration with heart disease: evidence from NHANES 2003/06. PLoS ONE: 2010; 5 1 e8673
90. Melzer D., Osborne N. J., Henley W. E., et al. Urinary bisphenol A concentration and risk of future coronary artery disease in apparently healthy men and women. Circulation: 2012; 125 12 1482 1490
91. Shankar A., Teppala S., Sabanayagam C. Bisphenol A and peripheral arterial disease: results from the NHANES. Environ Health Perspect: 2012; 120 9 1297 1300
92. Sabanayagam C., Teppala S., Shankar A. Relationship between urinary bisphenol A levels and prediabetes among subjects free of diabetes. Acta Diabetol: 2013; 50 4 625 631
93. Lang I. A., Galloway T. S., Scarlett A., et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA: 2008; 300 11 1303 1310
94. Wang T., Li M., Chen B., et al. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab: 2012; 97 2 E223 E227
95. Shankar A., Teppala S. Urinary bisphenol A and hypertension in a multiethnic sample of US adults. J Environ Public Health: 2012; 2012 481641
96. Batista T. M., Alonso-Magdalena P., Vieira E., et al. Short-term treatment with bisphenol-A leads to metabolic abnormalities in adult male mice. PLoS ONE: 2012; 7 3 e33814
97. Alonso-Magdalena P., Morimoto S., Ripoll C., Fuentes E., Nadal A. The estrogenic effect of bisphenol A disrupts pancreatic β-cell function in vivo and induces insulin resistance. Environ Health Perspect: 2006; 114 1 106 112 (Pubitemid 43056876)
98. Ropero A. B., Alonso-Magdalena P., García-García E., Ripoll C., Fuentes E., Nadal A. Bisphenol-A disruption of the endocrine pancreas and blood glucose homeostasis. Int J Androl: 2008; 31 2 194 200
99. Alonso-Magdalena P., Vieira E., Soriano S., et al. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect: 2010; 118 9 1243 1250
100. Angle B. M., Do R. P., Ponzi D., et al. Metabolic disruption in male mice due to fetal exposure to low but not high doses of bisphenol A (BPA): evidence for effects on body weight, food intake, adipocytes, leptin, adiponectin, insulin and glucose regulation. Reprod Toxicol: 2013; 42 256 268
101. Makaji E., Raha S., Wade M. G., Holloway A. C. Effect of environmental contaminants on Beta cell function. Int J Toxicol: 2011; 30 4 410 418
102. Escobar-Morreale H. F., San Millán J. L. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab: 2007; 18 7 266 272 (Pubitemid 47332217)
103. Legro R. S. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med: 2012; 30 6 496 506
104. Manikkam M., Tracey R., Guerrero-Bosagna C., Skinner M. K. Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. PLoS ONE: 2013; 8 1 e55387
105. Tracey R., Manikkam M., Guerrero-Bosagna C., Skinner M. K. Hydrocarbons (jet fuel JP-8) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. Reprod Toxicol: 2013; 36 104 116
106. Manikkam M., Tracey R., Guerrero-Bosagna C., Skinner M. K. Dioxin (TCDD) induces epigenetic transgenerational inheritance of adult onset disease and sperm epimutations. PLoS ONE: 2012; 7 9 e46249
107. Nilsson E., Larsen G., Manikkam M., Guerrero-Bosagna C., Savenkova M. I., Skinner M. K. Environmentally induced epigenetic transgenerational inheritance of ovarian disease. PLoS ONE: 2012; 7 5 e36129
108. Cory-Slechta D. A. Studying toxicants as single chemicals: does this strategy adequately identify neurotoxic risk? Neurotoxicology: 2005; 26 4 491 510 (Pubitemid 41178971)